A Phase 1 study of KBP-5209 in patients with advanced solid tumors
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to find the highest dose of study drug (KBP-5209) that can be given safely in humans, and to determine the immediate and long-term side effects of treatment with KBP-5209 when it is taken orally every day on a continuous basis.
Description
The purpose of this study is to establish a safe dose range based on side effects and to get an idea of how well the drug might work in treating cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
solid tumor
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
20 Nov 2022.
Study ID: 1501374278 (5209-CPK-1001